𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase

✍ Scribed by Jaideep Gogtay; Siddharth Chahchad; Sonali Jadhav; Shrinivas Purandare

Book ID
107619164
Publisher
Carden Jennings Publishing
Year
2010
Tongue
English
Weight
108 KB
Volume
92
Category
Article
ISSN
0925-5710

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Erythropoietin is effective in improving
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase
✍ Jorge Cortes; Susan O'Brien; Alfonso Quintas; Francis Giles; Jianquin Shan; Mary πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 104 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Myelosuppression occurs in up to 50% of patients with chronic myeloid leukemia (CML) who are treated with imatinib and β‰₯ Grade 3 myelosuppression is reported in approximately 10% of patients. ## METHODS The authors investigated the prognostic significance of anemia occu

Significance of suboptimal response to i
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
✍ Yesid Alvarado; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Gautam Borthakur πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 338 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during